Reply Hazy
Merck Can't Say How Good its Good News Is
It seems to have a solid lead in the IO market, but fortunes change quickly.
This article is for subscribers only.
Merck & Co.'s 2017 just got a whole lot brighter.
The company announced Wednesday evening that its immune-boosting cancer drug Keytruda can now be prescribed in combination with chemotherapy, vaulting it ahead of its rivals in the space. It's huge news. But exactly how huge it is going forward is largely out of Merck's control.